FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Histidine topics
Amino Acid
Amino Acids
Genetically
Antibodies
Immunoglobulin
Polypeptide
Nucleic Acid
Pertuzumab
Trastuzumab
Mesoporous Silica
Hemoglobin
Specificity
Carrier Molecule
Blood Plasma
Recombinant

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Histidine patents



      
           
This page is updated frequently with new Histidine-related patent applications. Subscribe to the Histidine RSS feed to automatically get the update: related Histidine RSS feeds. RSS updates for this page: Histidine RSS RSS


Methods of predicting and decreasing the risk of pre-term birth

University Of Louisville Research Foundation

Methods of predicting and decreasing the risk of pre-term birth

Methods of predicting and decreasing the risk of pre-term birth

Research & Business Foundation Sungkyunkwan University

Mutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr

Date/App# patent app List of recent Histidine-related patents
06/25/15
20150174208
 Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly patent thumbnailCosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly
The invention is a cosmetic and pharmaceutical liposomal composition which comprises a mixture of carboxylated oligopeptides derived from natural polypeptides; insulin; hyaluronidase and collagenase by their enzymatic hydrolysis; followed by a carboxylation of the free amino groups of lysine, histidine, and additional hydrolysis of terminal amino groups in the oligopeptides. Natural polypeptides may be hydrolyzed with a proteolytic enzyme to form a mixture of oligopeptides and succinylated them.
06/18/15
20150166620
 Vaccine patent thumbnailVaccine
The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (x3)mkdx2qlgx1 (seq id no. 99), wherein x1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, x2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine.
Affiris Ag
06/11/15
20150160230
 Methods of predicting and decreasing the risk of pre-term birth patent thumbnailMethods of predicting and decreasing the risk of pre-term birth
Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for participation in a clinical study, and for decreasing the risk of pre-term birth in a subject. These methods include providing a sample from the subject and detecting the level of one or more of growth arrest-specific protein 1 (gasi), alli-fused gene from chromosome 4 protein (ar4)/fragile x mental retardation 2 (fmr2) family member 3 (aff3), transthyretin (ttr), ryanodine receptor 1 (ryri), e26 transformation specific variant 6 (etv6), claudin-10, zinc finger protein 23 (znf23), collagen type xxvii α1 (col27ai), kazrin isoform-1, keratin-associated protein 10-9 (krtapio-9), huntingtin (htt), microtubule associated protein 9 (map9), coiled-coil domain-containing protein 13 (ccdc13), inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase isoform 2 (hisppdi), immunoglobulin gamma-3 chain c (ig-hg3), cysteine- and histidine-rich protein-1 (cyhri), and xp 002348181..
University Of Louisville Research Foundation, Inc.
06/11/15
20150159146
 Mutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr patent thumbnailMutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr
A dna polymerase (neq dna polymerase) derived from nanoarchaeum equitans is split into neq l and neq s fragments, each of which contains inteins. A neq hot-start (hs) dna polymerase in which the inteins of the neq l and neq s fragments are linked with each other is provided in the form of a precursor of neq dna polymerase.
Research & Business Foundation Sungkyunkwan University
06/04/15
20150151974
 Method for preparing zinc-histidine self-assembly biomimetric complex, zinc-histidine self-assembly complex prepared by said method, and  reducing carbon dioxide using said zinc-histidine self-assembly complex patent thumbnailMethod for preparing zinc-histidine self-assembly biomimetric complex, zinc-histidine self-assembly complex prepared by said method, and reducing carbon dioxide using said zinc-histidine self-assembly complex
Method for preparing zinc-histidine self-assembly biomimetic complex activating reaction to convert carbon dioxide into bicarbonate ion, zinc-histidine self-assembly biomimetic complex by preparation method, and method for reducing carbon dioxide using zinc-histidine self-assembly biomimetic complex. The preparation includes: mixing l-histidine and p-toluene sulfonic acid in first organic solvent to form first mixed solution and recrystallizing first mixed solution with ethyl ether to prepare first mixed substance: mixing first mixed substance with azelaic acid in second organic solvent to form second mixed substance containing imidazole and amide groups; mixing second mixed substance with naoh and hcl in third organic solvent to form third mixed solution and recrystallizing third mixed solution with ethyl ether to prepare third mixed substance having amphiphilic characteristic: and mixing third mixed substance with aqueous solution of zinc precursor and causing self-assembly to prepare zinc-containing self-assembly biomimetic complex..
Industry-academic Cooperation Foundation Yonsei University
06/04/15
20150150982
 Pharmaceutical formulation for a therapeutic antibody patent thumbnailPharmaceutical formulation for a therapeutic antibody
The present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least acetate/acidic acid, arginine, and trehalose. In addition, the present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least histidine, mannitol and/or succinate and trehalose..
Boehringer Ingelheim International Gmbh
06/04/15
20150150964
 Herpesvirus compositions and related methods patent thumbnailHerpesvirus compositions and related methods
The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization..
Sanofi Pasteur Biologics, Llc
05/21/15
20150141322
 Therapeutic agent, treatment method and inspection  diseases caused by activation or neutrophils patent thumbnailTherapeutic agent, treatment method and inspection diseases caused by activation or neutrophils
The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (hrg) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation.
National University Corporation Okayama University
05/21/15
20150140139
 Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same patent thumbnailComposition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same
The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. Ala, which is the photosensitizer of the present invention, is preferably activated by led radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm.
Gwangju Institute Of Science And Technology
05/14/15
20150132279
 Radiation sterilization-resistant protein composition patent thumbnailRadiation sterilization-resistant protein composition
A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.. .
05/07/15
20150122271

Thermal treatment process for tobacco materials


A method of preparing a tobacco material for use in a smoking article is provided, including (i) mixing a tobacco material, water, and an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, di- and trivalent cations, asparaginase, saccharides, phenolic compounds, reducing agents, compounds having a free thiol group, oxidizing agents, oxidation catalysts, plant extracts, and combinations thereof; (ii) heating the mixture; and (iii) incorporating the heat-treated mixture into a smoking article as a smokable material. A smoking article in the form of a cigarette is also provided that includes a tobacco material pre-treated to inhibit reaction of asparagine to form acrylamide in mainstream smoke.
R. J. Reynolds Tobacco Company
04/30/15
20150119556

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.
04/30/15
20150118322

Biomedical composition


The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or c4-c20 alkane, wherein the modified histidine and the polymer or c4-c20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or c4-c20 alkane is about 0-40%.. .
Industrial Technology Research Institute
04/23/15
20150112047

Adapter molecule capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag and methods of using the same


Disclosed is a bifunctional adapter molecule comprising two binding moieties a and b, the adapter molecule being capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag, wherein the binding moiety a comprises at least two chelating groups k, wherein each chelating group is capable of binding to a transition metal ion, thereby rendering moiety a capable of binding to an oligohistidine affinity tag, and the binding moiety b is an affinity tag other than an oligohistidine tag.. .
Iba Gmbh
03/26/15
20150086537

Highly concentrated pharmaceutical formulations


The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody, such as e.g. Rituximab, ocrelizumab, or humab<cd20>, or a mixture of such antibody molecules for subcutaneous injection.
Genentech, Inc.
03/19/15
20150080554

Affinity chromatography matrix


The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal protein a (e, d, a, b, c) or protein z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to h18 of the b domain of protein a or of protein z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to h18 of the b domain of protein a or of protein z is not serine, threonine or lysine.. .
Ge Healthcare Bio-sciences Ab
03/19/15
20150080291

Short antimicrobial lipopeptides


Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of kpv or kdpt that exhibit antimicrobial activity.
Helix Biomedix Inc.
03/12/15
20150071959

Neisseria meningitidis compositions and methods thereof


In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride.
Pfizer Inc.
03/12/15
20150071944

Stable antibody compositions and methods of stabilizing same


The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human igg molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of il-12/il-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation..
Abbvie, Inc.
03/05/15
20150065395

Compositions and methods for analyzing histidine phosphorylation


A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi
02/26/15
20150056696

Recombinant lentiviral vector preparation


Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a ph value of the preparation in the range of 6.0-8.0; and c) a carbohydrate.. .
Beijing Solobio Genetechnology Company Ltd.
02/12/15
20150045219

Abiotic and biotic stress tolerance peptides and polynucleotides, and compositions and methods comprising them


X is an amino acid chosen from alanine (a), cysteine (c), aspartic acid (d), glutamic acid (e), phenylalanine (f), glycine (g), histidine (h), isoleucine (i), lysine (k), leucine (l), methionine (m), asparagine (n), proline (p), glutamine (q), arginine (r), serine (s), threonine (t), valine (v), tryptophan (w), or tyrosine (y); (c) growing the plant to produce developed seeds from the plant comprising defenses induced by the defense activators.. .
02/05/15
20150037866

Composition, method and kit for obtaining purified recombinant proteins


Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate..
New England Biolabs, Inc.
01/29/15
20150030693

Anti-tumor aqueous solution, anti-cancer agent, and methods for producing said aqueous solution and said anti-cancer agent


An object of the present invention is to provide an antitumor aqueous solution and an anticancer agent, both of which can kill cancer cells while having virtually no effects on normal cells, and to provide methods for producing the antitumor aqueous solution and the anticancer agent. The method of the invention for producing an antitumor aqueous solution for killing cancer cells includes an aqueous solution preparation step of preparing an aqueous solution through addition, to water, of a solute containing at least one of disodium hydrogen phosphate (na2hpo4), sodium hydrogen carbonate (nahco3), l-glutamine, l-histidine, and l-tyrosine disodium dihydrate (l-tyrosine.2na.2h2o); and a plasma irradiation step of irradiating the aqueous solution with atmospheric pressure plasma generated in a plasma generation region by means of a plasma generator..
Nu Eco Engineeering Co., Ltd.
01/08/15
20150010647

Methods for identifying fragile histidine triad (fhit) interaction and uses thereof


Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorders using the fhit gene.. .
The Ohio State University
01/01/15
20150004173

Compositions and methods for analyzing histidine phosphorylation


A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi
12/25/14
20140377851

Analysis device


A reagent including a combination of a polyanionic compound and a bivalent cationic compound contains one substance selected from the group consisting of succinic acid, gluconic acid, alanine, glycine, valine, histidine, maltitol, and mannitol or at least one compound of the substance. A dry state of the reagent and deliquescence can be improved..
Panasonic Healthcare Co., Ltd.
12/25/14
20140377150

Scandium extraction method


Provided is a method for selectively extracting and inexpensively recovering scandium from an acidic solution containing calcium, magnesium, and scandium. The scandium extraction method according to the present invention involves subjecting an acidic solution containing calcium, magnesium, and scandium to solvent extraction using an extraction agent consisting of an amide derivative represented by the general formula below.
Sumitomo Metal Mining Co.,ltd.
12/18/14
20140370000

Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph


The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral ph. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral ph.
Baxter Healthcare Sa
12/18/14
20140369992

C-terminally tethered amino acids and their fibrinolytic therapeutic uses


The present disclosure provides a c-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the c-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins..
Canadian Blood Services
11/27/14
20140349327

Method for producing fructosyl valyl histidine oxidase preparation


A method for producing a fvho preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, d-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried fvho preparation, comprising a step of allowing bicine to coexist.. .
11/20/14
20140343499

Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same


A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.
11/20/14
20140343013

Stabalized glycosaminoglycan preparations and related methods


Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
11/20/14
20140342994

Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof


Provided is a fusion protein comprising circularly permuted form of trail, and the fusion protein contains circularly permuted form of trail and oligopeptides located at the n-terminus and/or c-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines.
11/13/14
20140335036

Hair care conditioning composition comprising histidine


A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase.
11/06/14
20140330198

Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same


A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.
11/06/14
20140329711

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
11/06/14
20140328737

Cobalt extraction method


The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (i).
10/09/14
20140303099

Compositions and methods for improving cardiovascular health


Compositions and methods for improving cardiovascular health, especially in the elderly, by delivering a selection of essential amino acids selected from the group of histidine, isoleucine, leucine, valine, lysine, methionine, phenylalanine, threonine, and arginine, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.. .
09/25/14
20140287472

Method for producing l-amino acids using bacteriua of the enterobacteriaceae family


There is disclosed a method for producing l-amino acid, for example l-threonine, l-lysine, l-histidine, l-phenylalanine, l-arginine or l-glutamic acid, using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of d-xylose permease.. .
09/25/14
20140286969

Anti-egfr antibody drug conjugate formulations


The invention provides a stable formulation comprising an anti-egfr antibody drug conjugate (adc), including an anti-egfr antibody, e.g., antibody 1, conjugated to an auristatin, e.g., mmaf, histidine, a sugar, and a surfactant.. .
09/18/14
20140275493

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics


Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
09/18/14
20140274790

Igg-binding peptide and detecting and purifying igg using same


Provided is a peptide that specifically or selectively binds to human igg. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human igg, wherein the amino acid sequence is represented by formula i: (x1-3)-c-(x2)-h-r-g-(xaa1)-l-v-w-c-(x1-3), wherein, x each independently represents any amino acid residue except cysteine, c represents a cysteine residue, h represents a histidine residue, r represents an arginine residue, g represents a glycine residue, xaa1 represents a glutamic acid residue or an asparagine residue, l represents a leucine residue, v represents a valine residue, and w represents a tryptophan residue..
08/21/14
20140235503

Prediction glomerular filtration rate from urine samples after kidney transplantation


Disclosed is a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation to provide an information needed for predict renal function after the transplantation, more particularly to a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation, which comprises detecting metabolic profiles of five biomarkers, 5a-androst-3-en-17-one (as), glycocholic acid (gc), sphingosine (sg), tryptophan (tr) and histidine (ht), from urine samples of patients. Glomerular filtration rate (gfr) after kidney transplantation can be predicted more rapidly and precisely to provide an information needed for predict renal function after the transplantation by using five metabolites as biomarkers.
08/21/14
20140234187

Valuable metal extraction agent and valuable metal extraction method using said extraction agent


The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula.
08/14/14
20140227728

Novel fructosyl peptidyl oxidase


In one form, a fructosyl peptidyl oxidase derived from a budding yeast phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying hba1c with higher sensitivity and specificity.
08/07/14
20140220644

Improved nitrile hydratase


Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
08/07/14
20140220147

Pharmaceutical composition comprising factor vii encapsulated in micelles


The invention relates to a pharmaceutical composition comprising factor vii encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the group consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.. .
07/24/14
20140206533

Organic syringomycin methods and compositions


Methods and materials for producing organic syringomycin, the methods include culturing a culture of pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a ph of from about 6.5 to 7; extracting syringomycin from the culture to yield an extract; and purifying the extract to yield syringomycin.. .
07/24/14
20140205711

Dipeptides as feed additives


The invention relates to feed additives containing dipeptides or salts thereof, in which one amino acid residue of the dipeptide is a dl-methionyl residue and the other amino acid residue of the dipeptide is an amino acid in the l-configuration selected from lysine, threonine, tryptophan, histidine, valine, leucine, isoleucine, phenylalanine, arginine, cysteine and cystine; feed mixtures containing these additives and method of producing the dipeptides.. .
07/17/14
20140199303

Stable liquid formulation of etanercept


The present invention relates to a stable liquid formulation of etanercept (recombinant p75 stnfr:fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage.
07/10/14
20140194359

Interfering rna delivery system and uses thereof


The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
07/03/14
20140186415

Polymer composition and polymer material


A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group..
06/26/14
20140179898

Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent


A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140178460

Lyase enzymes, nucleic acids encoding them and methods for making and using them


This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
06/12/14
20140161723

In vivo methods of monitoring biodistribution


Functional-lipid constructs of the structure f-s-l are disclosed, wherein f comprises a tyrosine or histidine residue, s is a spacer covalently linking f to l and l is a lipid. The functional residue may be iodinated and used to radiolabel a biological entity with 1251 and the iodinated constructs are used in a non-invasive method of monitoring the distribution of a biological entity in vivo..
06/05/14
20140155449

New use of l-histidine and derivatives thereof


The present invention discloses the use of l-histidine to reduce gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of l-histidine to prevent the nsf syndrome in patients with renal functionality impairment.
06/05/14
20140154752

Glycoside hydrolases having multiple hydrolase activities


Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.
05/29/14
20140148532

Adhesive composition


A adhesive composition that includes at least the main components of a hydrolyzable tannin and at least one cationic polymer selected from the group including (poly-)lysine, (poly-)-dl-ornithine, ε-poly-ornithine, (poly-)arginine, (poly-)glutamine, (poly-)asparagine, (poly-)histidine, (poly-)proline, putrescine, spermidine, spermine, cadaverine, agmatine, citrulline and mixtures thereof.. .
05/15/14
20140134232

Encapsulation of plasmid dna (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes


A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between dna with cationic lipid molecules and fusogenic/nls peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or nls at their one end.
05/08/14
20140127693

Fertilization prediction and promotion


The outcome of an in vitro fertilization (ivf) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (hrg) gene or protein analysis of hrg. The proline isoform of hrg or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman..
05/08/14
20140127144

Flavour modifying compounds


Wherein r1 is h, or a substituted, unsubstituted, branched or unbranched c1-c5 alkyl group and, nhr2 is a residue of an amino acid, is selected from alanine (ala), cysteine (cys), aspartic acid (asp), phenylalanine (phe), glutamic acid (glu), histidine (his), isoleucine (ile), lysine (lys), leucine (leu), methionine (met), asparagines (asn), glutamine (gln), arginine (arg), serine (ser), theronine (thr), valine (val), tryptophan (trp), tyrosine(tyr) and glycine (gly), with the proviso that the compound is not n-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds..
04/17/14
20140106431

High fidelity thermostable ligase and uses thereof


The present invention is directed to a mutant thermostable ligase having substantially higher fidelity than either t4 ligase or thermus thermophilus ligase. The ligase of the present invention is a mutant of a wild-type thermostable ligase having a histidine adjacent a kxdg motif, where the mutant thermostable ligase has a mutation in its amino sequence where the histidine adjacent the kxdg motif in the wild-type thermostable ligase is replaced with an arginine, and wherein x is any amino acid.
04/10/14
20140099667

Bacteriorhodopsin fusion membrane protein expression system


An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a t7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to asn94 of seq id no: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant haloarcula marismortui bacteriorhodopsin/d94n (hmbri/d94n) or a haloquadratum walsbyi bacteriorhodopsin (hwbr); b) a target membrane protein; and c) a t7 promoter, operably linked to the mutant hmbri/d94n or hwbr and the target membrane protein.
04/03/14
20140093472

L-histidine in ophthalmic solutions


The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight l-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye..
03/27/14
20140088166

Process of making and using pharmaceutical formulations of antineoplastic agents


In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .
03/20/14
20140082760

Non-human animals expressing ph-sensitive immunoglobulin sequences


Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
03/13/14
20140072622

Vaccine against streptococcus pneumoniae


The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the polyhistidine triad family (e.g.


Popular terms: [SEARCH]

Histidine topics: Amino Acid, Amino Acids, Genetically, Antibodies, Immunoglobulin, Polypeptide, Nucleic Acid, Pertuzumab, Trastuzumab, Mesoporous Silica, Hemoglobin, Specificity, Carrier Molecule, Blood Plasma, Recombinant

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.4437

3192

2 - 1 - 71